This report thus points to a potential role for CTGF in the etiopathology of DC, and suggests that measures to target its expression or function (including agents that elevate cAMP) may usefully limit fibrosis in Dupuytren's contracture. The gene discussed is CCN2; the disease is dyskeratosis congenita.